Chromatics Releases Third Quarter Results.

NEW YORK--(BUSINESS WIRE)--Nov. 18, 1997--Chromatics Color Sciences International Inc. (NASDAQ:CCSI) announced its 1997 third quarter results.

Revenues for the quarter and nine-month period ended Sept. 30, 1997 were $52,100 and $160,100 respectively (a $32,800 and a $57,800 decrease in revenues from the respective periods in 1996). Chromatics incurred net losses of $1,099,400 (net loss of $0.15 per share) for the quarter ended Sept. 30, 1997 as compared to $1,163,700 (net loss of $0.21 per share) for the quarter ended Sept. 30, 1996. Net losses for the nine-month period ended Sept. 30, 1997 were $3,362,400 (net loss of $0.45 per share) as compared to $3,001,400 (net loss of $0.52 per share) for the same period in 1996. Loss per share for the 1997 quarter was favorably impacted by an increase of 2,140,663 weighted average number of shares outstanding as compared to the 1996 quarter. Similarly, in the first nine months in 1997, there was an increase of 1,701,459 weighted average number of shares outstanding as compared to the same period in 1996. The $361,000 increase in net losses for the nine-month period ended Sept. 30, 1997 as compared to the same period in 1996 is primarily attributable to increased expenses relating to the company's implementation of its long-range business plan to seek commercial applications of its intellectual properties and technologies in the medical field, including an increase in costs and expenses regarding FDA regulatory applications, patent applications and research and development expenses.

Chromatics Color Sciences International Inc. is engaged in the business of color science, including the scientific color measurement and classification of human skin, certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the cosmetic, beauty aid and fashion industries, as well as technology development for potential medical applications involving the detection and monitoring of certain diseases. The company's common stock is traded on NASDAQ under the symbol "CCSI."

Except for the historical information contained herein, certain of the matters discussed are forward-looking statements that are subject to material risks and uncertainties which may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, the availability of any needed financing, the company's ability to operate as a going concern, the company's ability to implement its long range business plan for various applications for its technologies, including medical and industrial applications, the impact of competition, the obtaining of and compliance with regulatory approvals applicable to proposed applications of the company's technology, the management of growth, and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission, including those set forth in its Form 10-KSB for the year ended Dec. 31, 1996 and its Form 10-QSB for the period ended Sept. 30, 1997. -0-

               Chromatics Color Sciences International
                    Consolidated Balance Sheets

                                  Sept. 30, 1997      Dec. 31, 1996
                                    (Unaudited)

                          ASSETS

CURRENT ASSETS:
  Cash and equivalents             $ 3,936,100        $ 5,352,400
  Accounts receivable,
   less allowance for doubtful
   accounts of $0 and $10,000 in
   1997 and 1996, respectively          92,400             87,400
  Inventories                          223,300            223,400
  Prepaid expenses and other assets     97,700             89,200
          Total current assets       4,349,500          5,752,400

Colormate(TM) units, less accumulated
 depreciation of $32,800 (1997)
 and $26,000 (1996)                    667,200            674,000

Property and equipment, at cost less
 accumulated depreciation of $224,800
 (1997) and $155,300 (1996)            312,800            293,700

Other Assets                            24,400             27,400
                                   $ 5,353,900        $ 6,747,500


                LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
  Notes payable - collateralized
   by equipment                    $     6,100        $    10,000
  Notes payable to related party       299,600            326,000
  Accounts payable and accrued
   expenses:
     Attorneys and accountants         306,600            269,700
     Consultants                        46,600             65,600
     Trade                             164,000            109,700
  Security deposits                         --             10,500
          Total current liabilities    822,900            791,500


COMMITMENTS AND CONTINGENCIES

Redeemable Class A preferred stock,
  par value $.01 per share:
     Authorized - 1,400,000 shares
     Issued and outstanding -
      1,380,000 shares at par and
      redemption value                  13,800             13,800

STOCKHOLDERS' EQUITY (DEFICIENCY)
  Common stock, par value $.001
   per share:
     Authorized - 50,000,000 shares
     Issued and outstanding -
      7,798,469 shares (1997) and
      7,168,730 (1996)                   7,800              7,200
  Capital in excess of par value    17,307,100         15,370,300
  Accumulated deficit              (12,797,700)        (9,435,300)
     Total stockholders' equity      4,517,200          5,942,200
                                   $ 5,353,900        $ 6,747,500
-0-

     Chromatics Color Sciences International, Inc. and Subsidary
                Consolidated Statements of Operations
                                 (Unaudited)

                               Three Months Ended    Nine Months Ended
                                    Sept. 30,             Sept. 30,
                                 1997      1996       1997       1996

REVENUES:
 Lease, license and service
  contracts                  $  9,000   $  1,500   $ 10,500   $ 66,100
 Interest income               42,900     82,700    148,600    151,700
 Other                            200        700      1,000        100
                               52,100     84,900    160,100    217,900

COSTS AND EXPENSES
 Food and Drug Adminstration
  ("FDA") medical application
  expenses                    213,000    408,700  1,022,100    821,000
Patent application costs
 (including $96,100 of FDA
 related costs and $80,800 of
 research and development
 costs for the three months
 ended Sept. 30, 1997 and
 $317,200 of FDA related
 costs and $141,800 of
 research and development
 costs for the nine months
 ended Sept. 30, 1997)        176,900    109,000    459,000    192,000

 Research and development
  costs                       183,800     58,200    301,200    168,600
 General and administrative:
  Compensation of officers
   and employees              182,600    160,600    530,900    540,600
  Compensation of consultants  43,200     78,100    138,200    177,800
 Legal fees                    47,300     41,700    203,100    238,300
 Accounting fees                9,500      6,800     31,100     46,800
 Rent and storage              49,800     48,200    152,400    151,000
 Legal settlement                  --    132,000         --    132,000
 Insurance                     51,600     50,100    164,000    146,500
 Travel and entertainment      13,600      2,000     17,600     26,100
 Repairs and maintenance       31,500     27,300     89,800     84,000
 Depreciation and amortization 26,600     24,800     79,400    156,800
 Payroll taxes                 16,800     14,900     70,400     65,200
 Stock administration fees     13,900      6,500     38,600     49,100
 Printing, press and promotion 30,300      2,100     45,000     15,300
 Corporate taxes               13,300      4,700     24,900     15,500
 Other                         41,200     30,600    134,500    133,700
 Interest                       6,600     42,300     20,300     59,000
                            1,151,500  1,248,600  3,522,500  3,219,300

NET LOSS                   (1,099,400)(1,163,700)(3,362,400)(3,001,400)

WEIGHTED AVERAGE NUMBER OF
 COMMON SHARES AND
 EQUIVALENTS OUTSTANDING    7,579,487  5,432,824  7,478,938  5,777,479

NET LOSS PER SHARE         $    (0.15) $   (0.21) $  (0.45) $   (0.52)

CONTACT: Chromatics Color Sciences International

Darby Macfarlane, 212/717-6544

Chief Executive Officer